Johnston, Adam Comment on Effects of Tax Law Change on Health Fraud Settlement Costs
February 23, 2018
BNA Health Care Daily
Partners Pam Johnston and Fred Adam are quoted in a BNA Health Care Daily Report article, “Tax Law Change May Raise Health Fraud Settlement Costs,” about the possible effects of a change in the tax rules governing the deduction of health care fraud settlement amounts.
A provision of the new tax reform act, signed into law on Dec. 22, requires a settling agency, like the Department of Justice, to state what portion of a False Claim Act settlement can be deducted as a business expense because it qualifies as restitution. The tax provision also eliminates certain types of previously deductible expenses related to FCA settlements, like government investigation expenses and interest.
Johnston said the new deductibility rules will “materially affect negotiations with the DOJ” over FCA settlements because limiting the deduction of the settlement amount could make the settlement less attractive.
Adam said the new provision “increases costs for both sides, for taxpayers and for the government.”
Subscription required to read.
A provision of the new tax reform act, signed into law on Dec. 22, requires a settling agency, like the Department of Justice, to state what portion of a False Claim Act settlement can be deducted as a business expense because it qualifies as restitution. The tax provision also eliminates certain types of previously deductible expenses related to FCA settlements, like government investigation expenses and interest.
Johnston said the new deductibility rules will “materially affect negotiations with the DOJ” over FCA settlements because limiting the deduction of the settlement amount could make the settlement less attractive.
Adam said the new provision “increases costs for both sides, for taxpayers and for the government.”
Subscription required to read.
People
Related News
April 3, 2026
In the News
David Rosen Weighs in on FDA's Pharma PR Crackdown – 'Stick to the Data'
Foley & Lardner LLP partner David Rosen shared insights on the regulatory challenges pharmaceutical companies face when publicly communicating around new cancer therapies in the MM+M article, “When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio.”
April 2, 2026
In the News
Susan Poll Klaessy and Adrienne Walker Named Chair and Vice Chair of Foley’s Bankruptcy & Business Reorganizations Practice
Foley & Lardner LLP partner Susan Poll Klaessy was appointed chair of the firm’s global Bankruptcy & Business Reorganizations Practice Group. Partner Adrienne Walker will serve as vice chair, supporting the continued growth and strategic direction of the practice.
April 1, 2026
In the News
Foley Featured on Top 10 Sales of 2025 List by Golf Inc.
Foley & Lardner LLP advised on two transactions named among Golf Inc.’s Top 10 Sales of 2025.